[Asia Economy Reporter Gong Byung-sun] Celltrion announced on the 26th that it has signed a supply reservation contract for the COVID-19 antibody treatment Regkirona worth 48.5 billion KRW with its affiliate Celltrion Healthcare.



This amounts to approximately 2.62% of recent sales revenue.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing